Novel pathway in Bcr-Abl signal transduction involves Akt-independent, PLC-γ1-driven activation of mTOR/p70S6-kinase pathway

Oncogene

Volumn 29, Issue 5, 2010, Pages 739-751

  Markova, B ^a,e   Albers, C ^b   Breitenbuecher, F ^a,e   Melo, J V ^c   Brummendorf T H ^d   Heidel, F ^e,f   Lipka, D ^e,f   Duyster, J ^b   Huber, C ^e   Fischer, T ^e,f  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c INSTITUTE OF MEDICAL AND VETERINARY SCIENCE   (Australia)

^d UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^e JOHANNES GUTENBERG UNIVERSITY   (Germany)

^f OTTO VON GUERICKE UNIVERSITY   (Germany)

Author keywords

Bcr Abl; CML; MTOR; P70S6 kinase; PLC g1; Signaling

Indexed keywords

BCR ABL PROTEIN; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE; IMATINIB; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHOLIPASE C GAMMA1; PROTEIN KINASE B; PROTEIN KINASE C; S6 KINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CALCIUM SIGNALING; CELL DEATH; CELL PROLIFERATION; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DEPHOSPHORYLATION; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; FEMALE; LEUKEMIA CELL; LEUKEMOGENESIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; SIGNAL TRANSDUCTION;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; ENZYME ACTIVATION; FUSION PROTEINS, BCR-ABL; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MICE; PHOSPHOLIPASE C GAMMA; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS C-AKT; PYRIMIDINES; RIBOSOMAL PROTEIN S6 KINASES, 70-KDA; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION;

MAMMALIA;

EID: 76349109033     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2009.374     Document Type: Article

References (45)

1. Arvisais EW, Romanelli A, Hou X, Davis JS. (2006). AKT-independent phosphorylation of TSC2 and activation of mTOR and ribosomal protein S6 kinase signaling by prostaglandin F2alpha. J Biol Chem 281: 26904-26913.
2. Bartolovic K, Balabanov S, Hartmann U, Komor M, Boehmler AM, Buhring HJ, et al. (2004). Inhibitory effect of imatinib on normal progenitor cells in vitro. Blood 103: 523-529.
3. Brunn GJ, Williams J, Sabers C, Wiederrecht G, Lawrence Jr JC, Abraham RT. (1996). Direct inhibition of the signaling functions of the mammalian target of rapamycin by the phosphoinositide 3-kinase inhibitors, wortmannin and LY294002. EMBO J 15: 5256-5267.
4. Burchert A, Wang Y, Cai D, von Bubnoff N, Paschka P, Muller-Brusselbach S, et al. (2005). Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development. Leukemia 19: 1774-1782.
5. Copland M, Pellicano F, Richmond L, Allan EK, Hamilton A, Lee FY, et al. (2007). BMS-214662 potently induces apoptosis of chronic myeloid leukemia stem and progenitor cells and synergises with tyrosine kinase inhibitors. Blood 111: 2843-2853.
6. Dengler J, von Bubnoff N, Decker T, Peschel C, Duyster J. (2005). Combination of imatinib with rapamycin or RAD001 acts synergistically only in Bcr-Abl-positive cells with moderate resistance to imatinib. Leukemia 19: 1835-1838.
7. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, et al. (2001). Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344: 1031-1037.
8. Easton JB, Houghton PJ. (2006). mTOR and cancer therapy. Oncogene 25: 6436-6446.
9. Edinger AL, Thompson CB. (2002). Akt maintains cell size and survival by increasing mTOR-dependent nutrient uptake. Mol Biol Cell 13: 2276-2288.
10. Falasca M, Logan SK, Lehto VP, Baccante G, Lemmon MA, Schlessinger J. (1998). Activation of phospholipase C gamma by PI 3-kinase-induced PH domain-mediated membrane targeting. EMBO J 17: 414-422.
11. Giles FJ, Albitar M. (2005). Mammalian target of rapamycin as a therapeutic target in leukemia. Curr Mol Med 5: 653-661.
12. Gotoh A, Miyazawa K, Ohyashiki K, Toyama K. (1994). Potential molecules implicated in downstream signaling pathways of p185BCR-ABL in Ph+ ALL involve GTPase-activating protein, phospholipase C-gamma 1, and phosphatidylinositol 3-kinase. Leukemia 8: 115-120.
13. Grandage VL, Gale RE, Linch DC, Khwaja A. (2005). PI3-kinase/Akt is constitutively active in primary acute myeloid leukaemia cells and regulates survival and chemoresistance via NF-kappaB, Mapkinase and p53 pathways. Leukemia 19: 586-594.
14. Hay N, Sonenberg N. (2004). Upstream and downstream of mTOR. Genes Dev 18: 1926-1945.
15. Heidel F, Solem FK, Breitenbuecher F, Lipka DB, Kasper S, Thiede MH, et al. (2006). Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia by mutation of Asn-676 in the FLT3 tyrosine kinase domain. Blood 107: 293-300.
16. Kharas MG, Fruman DA. (2005). ABL oncogenes and phosphoinosi-tide 3-kinase: mechanism of activation and downstream effectors. Cancer Res 65: 2047-2053.
17. Kim HK, Kim JW, Zilberstein A, Margolis B, Kim JG, Schlessinger J, et al. (1991). PDGF stimulation of inositol phospholipid hydrolysis requires PLC-gamma 1 phosphorylation on tyrosine residues 783 and 1254. Cell 65: 435-441.
18. Kim JW, Sim SS, Kim UH, Nishibe S, Wahl MI, Carpenter G, et al. (1990). Tyrosine residues in bovine phospholipase C-gamma phosphorylated by the epidermal growth factor receptor in vitro. J Biol Chem 265: 3940-3943.
19. Kindler T, Breitenbuecher F, Kasper S, Stevens T, Carius B, Gschaidmeier H, et al. (2003). In BCR-ABL-positive cells, STAT-5 tyrosine-phosphorylation integrates signals induced by imatinib mesylate and Ara-C. Leukemia 17: 999-1009.
20. Konopka JB, Watanabe SM, Singer JW, Collins SJ, Witte ON. (1985). Cell lines and clinical isolates derived from Ph1-positive chronic myelogenous leukemia patients express c-abl proteins with a common structural alteration. Proc Natl Acad Sci USA 82: 1810-1814.
21. Liao HJ, Kume T, McKay C, Xu MJ, Ihle JN, Carpenter G. (2002). Absence of erythrogenesis and vasculogenesis in Plcg1-deficient mice. J Biol Chem 277: 9335-9341.
22. Ly C, Arechiga AF, Melo JV, Walsh CM, Ong ST. (2003). Bcr-Abl kinase modulates the translation regulators ribosomal protein S6 and 4E-BP1 in chronic myelogenous leukemia cells via the mammalian target of rapamycin. Cancer Res 63: 5716-5722.
23. Maffucci T, Falasca M. (2007). Phosphoinositide 3-kinase-dependent regulation of phospholipase Cgamma. Biochem Soc Trans 35: 229-230.
24. Mahon FX, Deininger MW, Schultheis B, Chabrol J, Reiffers J, Goldman JM, et al. (2000). Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. Blood 96: 1070-1079.
25. Marley SB, Gordon MY. (2005). Chronic myeloid leukaemia: stem cell derived but progenitor cell driven. Clin Sci (Lond) 109: 13-25.
26. Marte BM, Meyer T, Stabel S, Standke GJ, Jaken S, Fabbro D, et al. (1994). Protein kinase C and mammary cell differentiation: involvement of protein kinase C alpha in the induction of beta-casein expression. Cell Growth Differ 5: 239-247.
27. Miething C, Feihl S, Mugler C, Grundler R, von Bubnoff N, Lordick F, et al. (2006). The Bcr-Abl mutations T315I and Y253H do not confer a growth advantage in the absence of imatinib. Leukemia 20: 650-657.
28. Mohi MG, Boulton C, Gu TL, Sternberg DW, Neuberg D, Griffin JD, et al. (2004). Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs. Proc Natl Acad Sci USA 101: 3130-3135.
29. Rameh LE, Rhee SG, Spokes K, Kazlauskas A, Cantley LC, Cantley LG. (1998). Phosphoinositide 3-kinase regulates phospho-lipase Cgamma-mediated calcium signaling. J Biol Chem 273: 23750-23757.
30. Ren R. (2005). Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia. Nat Rev Cancer 5: 172-183.
31. Ren SY, Xue F, Feng J, Skorski T. (2005). Intrinsic regulation of the interactions between the SH3 domain of p85 subunit of phospha-tidylinositol-3 kinase and the protein network of BCR/ABL oncogenic tyrosine kinase. Exp Hematol 33: 1222-1228.
32. Rhee S, Poulin B, Lee SB, Sekiya F. (2000) In: Cockroft S (ed). Biology of Phosphoinositides, vol.27. Oxford University Press: Oxford. Rhee SG. (2001). Regulation of phosphoinositide-specific phospholi-pase C. Annu Rev Biochem 70: 281-312.
33. Richardson CJ, Schalm SS, Blenis J. (2004). PI3-kinase and TOR: PIKTORing cell growth. Semin Cell Dev Biol 15: 147-159.
34. Saglio G, Cilloni D. (2004). Abl: the prototype of oncogenic fusion proteins. Cell Mol Life Sci 61: 2897-2911.
35. Sarbassov DD, Ali SM, Sabatini DM. (2005). Growing roles for the mTOR pathway. Curr Opin Cell Biol 17: 596-603.
36. Shaw RJ, Cantley LC. (2006). Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 441: 424-430.
37. Si J, Collins SJ. (2008). Activated Ca2+/calmodulin-dependent protein kinase IIgamma is a critical regulator of myeloid leukemia cell proliferation. Cancer Res 68: 3733-3742.
38. Skorski T, Bellacosa A, Nieborowska-Skorska M, Majewski M, Martinez R, Choi JK, et al. (1997). Transformation of hematopoietic cells by BCR/ABL requires activation of a PI-3k/Akt-dependent pathway. EMBO J 16: 6151-6161.
39. Skorski T, Kanakaraj P, Nieborowska-Skorska M, Ratajczak MZ, Wen SC, Zon G, et al. (1995). Phosphatidylinositol-3 kinase activity is regulated by BCR/ABL and is required for the growth of Philadelphia chromosome-positive cells. Blood 86: 726-736.
40. Van Etten RA. (2002). Studying the pathogenesis of BCR-ABL+ leukemia in mice. Oncogene 21: 8643-8651.
41. Walz C, Sattler M. (2006). Novel targeted therapies to overcome imatinib mesylate resistance in chronic myeloid leukemia (CML). Crit Rev Oncol Hematol 57: 145-164.
42. Wilde JI, Watson SP. (2001). Regulation of phospholipase C gamma isoforms in haematopoietic cells: why one, not the other? Cell Signal 13: 691-701.
43. Wing LY, Chen HM, Chuang PC, Wu MH, Tsai SJ. (2005). The mammalian target of rapamycin-p70 ribosomal S6 kinase but not phosphatidylinositol 3-kinase-Akt signaling is responsible for fibroblast growth factor-9-induced cell proliferation. J Biol Chem 280: 19937-19947.
44. Wlodarski P, Kasprzycka M, Liu X, Marzec M, Robertson ES, Slupianek A, et al. (2005). Activation of mammalian target of rapamycin in transformed B lymphocytes is nutrient dependent but independent of Akt, mitogen-activated protein kinase/extracellular signal-regulated kinase kinase, insulin growth factor-I, and serum. Cancer Res 65: 7800-7808.
45. Wullschleger S, Loewith R, Hall MN. (2006). TOR signaling in growth and metabolism. Cell 124: 471-484.